The effect of different preparations of hormone therapy on tumor necrosis factor-alpha levels in women with surgical menopause

Basit Öğe Kaydı
dc.contributor.authorSomunkıran, Aslı
dc.contributor.authorCoşkun, Abdurrahman
dc.contributor.authorDemirci, Fuat
dc.contributor.authorYücel, Oğuz
dc.date.accessioned2020-04-30T23:32:53Z
dc.date.available2020-04-30T23:32:53Z
dc.date.issued2008
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionCoskun, Abdurrahman/0000-0002-1273-0604en_US
dc.descriptionWOS: 000253751200005en_US
dc.descriptionPubMed: 18210330en_US
dc.description.abstractThe aim of the present prospective controlled study was to examine the influence of 17 beta-estradiol and tibolone on tumor necrosis factor-alpha (TNF-alpha) levels in healthy women with surgical menopause. Forty-five surgically menopausal women were included in the study. Thirty women were randomized to receive tibolone 2.5 mg or 17 beta-estradiol 2 mg daily for 16 weeks. Fifteen surgically menopausal women who refused hormone therapy served as controls. Serum was collected from the subjects at baseline and at the end of the study for TNF-alpha assay. Neither tibolone nor 17 beta-estradiol showed a significant influence on TNF-alpha level at the end of 16 weeks in comparison with baseline. Although tibolone induced a trend toward decreased level of TNF-alpha (3.30 +/- 0.42 vs. 2.56 +/- 1.94 mu g/dl), this was non-significant. The slight increase observed in TNF-alpha level in the control group was also insignificant (3.60 +/- 1.20 vs. 4.10 +/- 0.70 mu g/dl). Overall, these results demonstrate no significant effects of either tibolone or 17 beta-estradiol on circulating TNF-alpha level in surgically menopausal women. However, the significant difference achieved between the tibolone and control group after treatment is promising and needs to be investigated in trials with longer treatment periods.en_US
dc.identifier.doi10.1080/09513590701718307en_US
dc.identifier.endpage83en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage79en_US
dc.identifier.urihttps://doi.org/10.1080/09513590701718307
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4843
dc.identifier.volume24en_US
dc.identifier.wosWOS:000253751200005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthormone replacement therapyen_US
dc.subjectmenopauseen_US
dc.subjecttiboloneen_US
dc.subjecttumor necrosis factor-alphaen_US
dc.titleThe effect of different preparations of hormone therapy on tumor necrosis factor-alpha levels in women with surgical menopauseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4843.pdf
Boyut:
108.89 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu